Image courtesy: CDC

Article Writer-   Minakshi  Kumari, MSc. Biotechnology , RCA, Maharana Pratap University of Agriculture and Technology ,Udaipur, Rajsthan(India)

Drug Controller General of India (DCGI) has granted approval to India’s 1st indigenous conjugate vaccine for preventing pneumonia . This vaccine is known as the Pneumococcal polysaccharide conjugate vaccine and has been developed by Serum Institute of India Pvt. Ltd., the world’s largest vaccine manufacturer by a number of doses produced and sold globally. It took almost five years to develop and conduct global trials, before getting licensed. It is set to provide active immunization for pneumonia that is caused by Streptococcus pneumoniae. In this vaccine, the weak antigen is combined with strong antigen (carrier) to develop a strong immune response against the weak antigen, and the antibody so produced will be used for the conjugate vaccine. It is supposed to fulfill the global demand of 100 million doses over the next few years.